Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.
Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.
McKenna SP, Whalley D, Doward LC. No SF-36 please – we're British!. Proc Br Psychol Soc. 2001;9(1):70.
McKenna SP, Doward LC, van Assche D. Diabetic foot ulcers: a patients' perspective. Proc Br Psychol Soc. 2001;9(1):70.
Whalley D, Doward LC, McKenna SP. Urogenital atrophy: an accepted part of ageing? Proc Br Psychol Soc. 2001;9(1):78.
Doward LC, Whalley D, McKenna SP. Silent voices – hidden lives. Carer's perceptions of the impact of caring for a relative with Alzheimer's disease. Proc Br Psychol Soc. 2001;9(1):65.
Doward LC, Whalley D, McKenna SP. The development of the Alzheimer's Carers Quality of Life Instrument (ACQLI). Proc Br Psychol Soc. 2001;9(1):65.
Cook SA, Doward LC, McKenna SP, Erdman R, Niero M, van Assche D. Venous leg ulcers – patient-reported impact on quality of life. Proc Br Psychol Soc. 2001;9(1):64.
Dewar AL, Doward LC, Whalley D, McKenna SP, Tennant A, Emery P. Impact of systemic lupus erythematosus (SLE) experienced from the patients' perspective. Proc Br Psychol Soc. 2001;9(1):64.